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MaThe association of atrial ﬁbrillation (AF) with ischemic stroke has long been recognized; yet, the pathogenic mechanisms
underlying this relationship are incompletely understood. Clinical schemas, such as the CHA2DS2-VASc (congestive heart
failure, hypertension, age$75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 74 years,
sex category) score, incompletely account for thromboembolic risk, and emerging evidence suggests that stroke can occur in
patients with AF even after sinus rhythm is restored. Atrial ﬁbrosis correlates with both the persistence and burden of AF, and
gadolinium-enhanced magnetic resonance imaging is gaining utility for detection and quantiﬁcation of the ﬁbrotic substrate,
but methodological challenges limit its use. Factors related to evolution of the thrombogenic ﬁbrotic atrial cardiomyopathy
support the view that AF is a marker of stroke risk regardless of whether or not the arrhythmia is sustained. Antithrombotic
therapy should be guided by a comprehensive assessment of intrinsic risk rather than the presence or absence of AF at a
given time. (J Am Coll Cardiol 2015;65:2239–51) © 2015 by the American College of Cardiology Foundation.A trial ﬁbrillation (AF) occurs in patients with awide array of cardiovascular and noncardiacconditions, rising in incidence with patient
age to affect nearly one-quarter of the adult popula-
tion over their lifespan (1). Although the incidence
of AF may have plateaued, its prevalence is in-
creasing (1–3), and although the associated risk of
stroke may be decreasing (4,5), AF-associated mortal-
ity has not abated (2). The pathogenic mechanisms
linking AF with stroke are not simply that the left
atrium (LA) becomes effectively stationary as it ﬁbril-
lates, allowing stasis-induced thrombus in the left
atrial appendage (LAA) to dislodge and embolize
through the systemic circulation to the brain (6).
The risk of stroke in patients with AF lacking other
risk factors is barely distinguishable from that of pa-
tients without AF (7), and patients with paroxysmalm the Icahn School of Medicine at Mount Sinai, New York, New York.
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or paced (8–10). These observations suggest that
mechanisms other than stasis alone contribute to
the development of thromboembolic events in pa-
tients with AF.
The pathogenesis of thromboembolism in AF
involves endothelial dysfunction, abnormal ﬂow
patterns within the LAA, procoagulant properties of
the blood, inﬂammation, neurohumoral factors, and
structural pathology of the atrial myocardium. The
fundamental characteristic of the structural pathol-
ogy associated with AF is ﬁbrosis (Central Illustration).
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ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
AT = atrial tachyarrhythmia
Cav-1 = caveolin-1
CMR = cardiac magnetic
resonance
CRP = C-reactive protein
DE = delayed-enhancement
LA = left atrium
LAA = left atrial appendage
TGF = transforming growth
factor
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2240an array of ﬁbroproliferative signaling path-
ways (11–15).
The term ﬁbrotic atrial cardiomyopathywas
originally proposed by Kottkamp et al. (16) to
describe a speciﬁc, primary form of biatrial
pathology, characterized by extensive ﬁbrosis
as the substrate underlying atrial arrhythmias
and thromboembolism. As methods for
detection of atrial ﬁbrosis improved, the term
was applied to atrial ﬁbrotic changes devel-
oping in patients with various comorbidities
associated with AF and aging. Advances
in noninvasive cardiac imaging allow the
detection, localization, and quantiﬁcation ofatrial ﬁbrosis, which correlates with both the persis-
tence and cumulative burden of arrhythmia over
time and with related outcomes, such as stroke
(17), making the pathological hallmark an attractive
biomarker. But, whether atrial ﬁbrosis mediates
the relationship between arrhythmia and stroke is
not known. Post-mortem biopsies, electroanatomical
mapping studies, and delayed-enhancement (DE)
cardiac magnetic resonance (CMR) images demon-
strate more extensive ﬁbrosis in patients with persis-
tent AF, rather than paroxysmal AF, although there is
considerable variation (18–22). However, even suc-
cessful elimination of AF by ablation fails to halt the
progression of ﬁbrosis, suggesting that abnormalities
in the atrial substrate are not the result of arrhythmia
alone (23). Examination of atrial biopsies collected
during open-heart surgery demonstrated an associa-
tion between extent of atrial ﬁbrosis and age (24,25),
but the extent of ﬁbrosis observed in biopsies from
patients with AF was independent of age and com-
orbidity (18,26), suggesting that the relationship be-
tween age and ﬁbrosis is less important in AF.
CELLULAR SIGNALING PATHWAYS
MEDIATING ATRIAL FIBROSIS AND AF
At the tissue level, the atrial cardiomyopathy associ-
ated with AF comprises both myocyte degeneration
and ﬁbrotic changes of the connective extracellular
matrix (27). Fibroblasts, the most abundant cells in
the heart, preserve the collagen matrix surrounding
the larger cardiac myocytes that comprise the bulk of
cardiac tissue. Fibroblast proliferation, ﬁbrosis, and
accumulation of extracellular matrix proteins in the
myocardial interstitium engender AF by disrupting
electrical conduction. This predisposes to anisotropy
and re-entry, allowing proliferation of ectopic foci
and propagation of irregular wave fronts (28,29).
Collagen deposition proliferating in response to car-
diac injury and electrical derangements adds to avicious cycle in which “AF begets AF” (11). Rapid
atrial myocyte depolarization and atrial distension
contribute to accumulation of intracellular calcium
ions, triggering adaptive and inﬂammatory responses
that potentiate myocyte apoptosis and accelerate
ﬁbrosis (29). However, much remains mysterious
about the mechanisms of structural and electrical
atrial remodeling, the biophysical relationships be-
tween cardiac ﬁbroblasts and mechanical–functional
coupling, and the links between them in patients with
or predisposed to developing AF (30,31).
Histologically, atrial cardiomyocytes exhibit loss of
sarcomeres and accumulation of glycogen storage
granules, adaptive alterations in cellular metabolism
not unlike those observed in response to ischemia
(27). A principal mediator of AF-induced atrial car-
diomyocyte apoptosis and necrosis is calpain (32),
a protein concentrated in or near the nucleus and
intercalated sarcomeric discs, which is capable of
both proteolysis (33) and degradation of L-type Ca2þ
channels. Additional potential mediators of structural
remodeling include platelet-derived growth factor,
atrial natriuretic peptide, and galectin-3 (34–36).
The calcium-calcineurin nuclear factor of activated
T-cells (NFAT) pathway is involved in both myocyte
hypertrophy and interstitial ﬁbrosis (37). The atria of
patients with AF exhibit increased activation of calci-
neurin (38), and the dephosphorylation and trans-
location of the transcription factors NFAT3 and NFAT4
from the cytosol to the nucleus activate target genes
capable of inducing accumulation of collagen around
degenerating cardiomyocytes (39–41). Transforming
growth factor (TGF)-b1 is a key regulator of ﬁbrosis
that enhances collagen synthesis both in vitro and
in vivo, thereby affecting remodeling (42). Higher
levels of TGF-b1 are associated with more extensive
LA ﬁbrosis, even in patients clinically classiﬁed as
having lone AF. Calcineurin inhibitors, such as cyclo-
sporin A and FK506, down-regulate TGF-b1 expression
and reduce extracellular matrix protein accumu-
lation (43,44). Thus, enhanced TGF-b1 signaling ac-
tivity may mediate increased cardiac ﬁbrosis (45).
Caveolin-1 (Cav-1), a scaffolding protein that reg-
ulates signaling molecules, may have antiﬁbrotic ef-
fects in atrial tissue. Cav-1 is a negative regulator of
TGF-b1, and decreased Cav-1 enhances the activity of
TGF-b1 signaling pathways and increases collagen
production. Reduced expression of Cav-1 in patients
with AF could augment TGF-b1 proﬁbrotic signaling,
promoting atrial ﬁbrosis. Indeed, whereas TGF-b1
levels, collagen I and III content, and atrial ﬁbrosis
are increased in the atrial myocardium of patients
with AF, expression of Cav-1 is down-regulated.
In vitro Cav-1 gain-of-function in human atrial
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Factors that promote atrial ﬁbrillation (AF) contribute to the development of the ﬁbrotic substrate and arrhythmogenesis. In this proposed schema, the ﬁbrotic
substrate, AF-associated stasis, and inﬂammation are separate but inter-related pathways mediating thromboembolism.
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2241tissue specimens abolished TGF-b1-induced produc-
tion of collagens I and III, which suggested a possible
protective, antiﬁbrotic role for Cav-1 (46).
INFLAMMATORY CORRELATES OF
ATRIAL FIBROSIS AND THROMBOGENESIS
Markers of systemic inﬂammation, such as C-reactive
protein (CRP), tumor necrosis factor-a, interleukin-2,
-6, and -8, and monocyte chemoattractant protein-1,
rise in patients with AF. This raises the possibility
that inﬂammation contributes not only to the inception,recurrence, and perpetuation of AF, but also to
thrombus formation and ischemic events (47–52). After
adjustment for other clinical risk factors, inﬂammatory
biomarkers, including CRP, soluble intercellular adhe-
sion molecule-1, and ﬁbrinogen, independently corre-
lated with incident AF over more than a decade of
follow-up of a large cohort of women (53). The magni-
tude of elevations in plasma CRP and interleukin-6 is
probably related to atrial structural remodeling, as re-
ﬂected by LA enlargement and impaired LAA function.
Connections between inﬂammation and throm-
bosis could be mediated by endothelial injury, tissue
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factor, and P-selectin (54–57). Inﬂammatory markers
also correlate with endothelial dysfunction and
thrombin-mediated platelet aggregation. Early after
the onset of AF, P-selectin is expressed on the platelet
surface, whereas persistent AF is associated with
potentially thrombogenic interactions of inﬂamma-
tory monocytes with platelets and tissue factor (58).
These connections notwithstanding, only sparse data
are yet available to support the predictive value of
inﬂammatory biomarkers with respect to thrombo-
embolic events in patients with AF.
Thiazolidinediones, insulin-sensitizing drugs used
for treatment of patients with type 2 diabetes
mellitus, have pleiotropic anti-inﬂammatory and
antioxidant effects with the potential to modulate
cardiovascular remodeling. Pioglitazone, a peroxi-
some proliferator-activated receptor-g agonist, re-
sulted in attenuation of pressure overload-induced
LA ﬁbrosis (59). In another model, LA ﬁbrosis induced
by continuous infusion of angiotensin II was attenu-
ated by repeated whole-body hyperthermia that led
to induction of heat shock protein-72 (60). In a
nephrectomy model of AF associated with chronic
kidney disease, nicotinamide adenine dinucleotide
phosphate oxidase was increased and intervention
with a potent antioxidant effectively prevented AF-
associated ﬁbrosis (59). This suggests that oxidative
stress may be involved in the pathogenesis of LA
ﬁbrosis and vulnerability to AF and lends support to
the view that inﬂammatory proﬁbrotic processes are
important mediators of atrial ﬁbrosis (61).
Local epicardial adiposity predisposes to AF.
Pericardial fat is an ectopic deposit that shares its blood
supply with the coronary microcirculation. It is highly
metabolically active and elaborates inﬂammatory cy-
tokines, which may underlie the link between obesity
and AF (62). Increased pericardial fat was associated
with the prevalence of AF, even after adjustment for
conventional clinical risk factors (63). Pericardial fat
has also demonstrated a quantitatively-dependent
association with AF severity (64,65). In a sheep
model, progressive obesity is associated with expres-
sion of proﬁbrotic mediators that accompany electrical
and structural atrial remodeling (66). Among obese
patients with AF undergoing ablation procedures,
lifestyle changes resulting in weight loss, lower blood
pressure, and better glycemic control were associated
with more successful rhythm control, and reduction in
epicardial adiposity was implicated (67). Mechanistic
links between adiposity, diabetes, atrial ﬁbrosis, and
AF may involve oxidative stress, but further studies
are needed to advance from theoretical to pragmatic
constructs (68).Although inﬂammation is almost certainly a cause
and consequence of AF, correlations between the
clinical progression of AF and plasma levels of
inﬂammatory markers are relatively weak. Most
markers do not rise concurrently with transitions
from paroxysmal to persistent or permanent AF. An
exception is tumor necrosis factor-a, which exhibits a
graded increase as AF becomes more sustained. Also
uncertain is whether inﬂammation in patients with
AF is a local or a systemic process. Although AF may
contribute to inﬂammation, a key unanswered ques-
tion is whether the elevated inﬂammatory markers in
patients with AF are mediated by the dysrhythmia
itself, or by underlying cardiovascular disease.
GENETIC PREDISPOSITION AND EVOLUTION
OF THE FIBROTIC PHENOTYPE
Genome-wide association studies suggest that AF-
susceptibility variants may modulate atrial ﬁbrosis
(69). Among the candidate genes, PITX2 demon-
strates the most consistent association with AF and
ﬁbrosis. Animal models with PITX2c-deﬁciency
demonstrate a predisposition to atrial arrhythmias,
greater expression of collagen precursor genes, and
increased atrial ﬁbrosis on immunohistochemical
staining (70). ZFHX3 and Cav-1 also confer suscepti-
bility to AF and, as mentioned earlier, may mediate
the atrial ﬁbrotic substrate through effects on TGF-b
(46,71). Microribonucleic acids, protein kinases, and
other factors that regulate protein-coding genes may
determine individual vulnerability to AF. As an
example, selective inactivation of atrial cardio-
myocytemitogen-activated protein kinase-4 increases
the TGF-b1 signaling associated with atrial remodeling
and arrhythmogenesis (72). In a dog model of atrial
cardiomyopathy induced by simultaneous atrioven-
tricular pacing, omega-3 polyunsaturated fatty acids
alter expression of ﬁbrotic and hypertrophic genes,
prevent induction of AF, and reduce atrial ﬁbrosis
(73,74). Additional studies are needed to clarify the
mechanistic links between signaling molecules and
cellular effects, including those mediating inﬂamma-
tion and thrombogenesis.
DETECTION, LOCALIZATION AND
QUANTIFICATION OF ATRIAL FIBROSIS
Atrial ﬁbrosis is reﬂected echocardiographically by
changes in atrial deformation. Three-dimensional
(3D) speckle tracking has been used to predict re-
current AF following catheter ablation (75), and
attenuation of calibrated echocardiographic inte-
grated backscatter has also been associated with AF
recurrence (76,77). These methods provide only
FIGURE 1 3D Cardiac Magnetic Resonance Reconstructions of LA Fibrosis in the
RAO and PA Projections
Utah stage 1
Utah stage 3 Utah stage 4
Utah stage 2
Reconstructions are according to the percent of ﬁbrosis, as graded by the UTAH staging
system. UTAH I:<5% ﬁbrosis; II: 5% to 19% ﬁbrosis; III: 20% to 35% ﬁbrosis; and IV:>35%
ﬁbrosis. Green indicates LA ﬁbrosis. Reprinted with permission from Akoum et al. (96).
3D ¼ 3-dimensional; LA ¼ left atrium; PA ¼ postero-anterior; RAO ¼ right anterior oblique.
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2243semiquantitative estimates of the extent of atrial
ﬁbrosis and have not been validated by comparison
with surgical or post-mortem tissue biopsies. Sub-
clinical functional and hemodynamic abnormalities
associated with atrial ﬁbrotic cardiomyopathy are
associated with changes in global longitudinal strain,
an echocardiographic measure of the longitudinal
contraction of myocardial ﬁbers, even in patients
with normal left ventricular ejection fraction. The LA
volume index, LA ejection fraction, and atrial strain
rate are independent correlates of stroke, providing
further evidence linking impaired contractile,
conduit, and reservoir functions of the LA to stasis
and thromboembolism (78).
Tissue characterization of LA ﬁbrosis by DE-CMR
has been correlated with the extent of LA ﬁbrosis on
histological specimens of surgical biopsies and post-
mortem analysis (Figure 1) (79). The imaging agent
gadolinium shortens T1 enhancement of magnetized
tissue. It is taken up and quickly returned to the blood
pool by healthy tissue, but dissipates more slowly
from diseased tissue with extracellular ﬁbrosis. In
retrospective studies, the degree of atrial ﬁbrosis
detected by gadolinium-enhanced CMR correlates
with the incidence of stroke (80). This imaging mo-
dality might also guide patient selection for ablation,
as greater ﬁbrosis on DE-CMR has been associated
with recurrent AF after ablation (17,79).
Beyond the high level of expertise required for
image acquisition and the time required for image
processing, several challenges limit the use of 3D
DE-CMR for evaluation of atrial ﬁbrosis. Accurate 3D
imaging of the LA involves manual segmentation
from other images and careful intensity threshold
calibration to differentiate normal from ﬁbrotic tissue
(81) (Figure 2). Anatomic variability and imaging
artifacts may confound image processing. Among the
relevant patient factors are body size and habitus
that allow optimum image quality and adequate
heart rate control to facilitate gating (17). Automated
image processing and other technological advances
make DE-CMR a promising modality for character-
ization of the LA wall as an adjunct measure to
improve thromboembolic risk assessment.
Although the multicenter, prospective DECAAF
(Delayed-Enhancement MRI Determinant of Success-
ful Radiofrequency Catheter Ablation of Atrial
Fibrillation) study demonstrated that DE-CMR pre-
dicted AF recurrence after ablation (17), proprietary
software algorithms analyzed the images. Others re-
ported variable success in reproducing these ﬁndings,
attributed to ambiguity of LA boundaries during
segmentation, particularly at the level of the LA roof
and mitral annulus, and interobserver variability inquantiﬁcation of late gadolinium enhancement of the
LA (82). More accurate and reproducible standards for
segmentation of the LA and agreement upon
enhancement thresholds will likely improve repro-
ducibility of measurements of LA wall ﬁbrosis (81)
and expand the utility of DE-CMR to predict throm-
boembolic risk in patients with AF.
Others have suggested a relationship between
thromboembolic risk and LAA morphology on com-
puted tomography and CMR, classifying the spatial
arrangement of the LAA lobes into the cactus, chicken
wing, windsock, and cauliﬂower forms (83). In
a group of patients with AF, those with the most
prevalent LAA morphology, the chicken wing
(approximately 48% of the cohort), were less likely to
have a history of stroke or transient ischemic attack
after adjustment for other risk factors, including
CHADS2 (congestive heart failure, hypertension, age
>75 years, diabetes mellitus, stroke) score. Those
with other morphologies were 10 times as likely to
have experienced prior stroke or transient ischemic
attack. Whether morphology is associated with the
degree of atrial ﬁbrosis has not been investigated.
ATRIAL FIBROSIS AND STROKE RISK
IN PATIENTS WITH AF
The absolute risk of stroke associated with AF is vari-
able and derives from biological factors and comor-
bidities that promote the thrombogenic substrate of
AF. Prediction models quantify individual stroke
risk, enhance cost-effective therapy, and help guide
assessment of whether the beneﬁt of anticoagulation
FIGURE 2 Cardiac Magnetic Resonance Imaging: Segmentation of the LA
Acquisition of high-resolution 3D delayed-enhancement cardiac magnetic resonance (CMR)
imaging of the LA (step 1). The LA wall is deﬁned by identiﬁcation of epicardial and
endocardial borders in each cardiac magnetic resonance (CMR) section (step 2). Wall
segmentations include both the LA wall and the antral regions of the pulmonary veins, but
exclude the mitral valve. Fibrosis is quantiﬁed on the basis of the relative intensity of
contrast enhancement (step 3). The 3D model of the LA is rendered from the endocardial
(LA cavity) and LA wall segmentations, and the maximum enhancement intensities are
projected on the surface of the model (step 4). Images provided courtesy of Dr. Nassir
Marrouche and Dr. Alan Morris, University of Utah. Abbreviations as in Figure 1.
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Investigators pooled data from early trials to form a
stroke classiﬁcation scheme that included age, prior
cerebral ischemia (either stroke or transient ischemic
attack), hypertension, and diabetesmellitus, as well as
coronary artery disease and heart failure (84). Simi-
larly, the SPAF (Stroke Prevention in Atrial Fibrilla-
tion) investigators identiﬁed hypertension (blood
pressure >160 mm Hg), prior cerebral ischemia, recent
clinical heart failure or left ventricular dysfunction, or
the combination of age >75 years and female sex (85).
Combining these into a risk-scoring system led to the
development of the CHADS2 score. Although CHADS2
provides a simple heuristic measure for predicting
individual risk of stroke, it accounts for only part of the
risk of stroke related to AF (c-statistic ¼ 0.570)
(86). Recent studies highlight the fact that patients
with a CHADS2 score of 0 are not all at low risk,
and anticoagulation decisions based simply on aCHADS2 score of 0 may be insufﬁcient to avoid stroke/
thromboembolism in patients with AF (87,88).
The CHA2DS2-VASc (congestive heart failure, hy-
pertension, age $75 years, diabetes mellitus, stroke/
transient ischemic attack, vascular disease, age 65 to
74 years, sex category) schema recognizes the rela-
tionship of stroke risk in patients with AF to age as a
continuous variable, acknowledges the higher risk of
stroke faced by women with AF, and incorporates the
less-validated risk associated with vascular disease,
history of myocardial infarction, complex aortic
plaque (89), and peripheral arterial disease, although
these may contribute unequally. Because of its
greater sensitivity, the CHA2DS2-VASc better excludes
lowest-risk patients from oral anticoagulant therapy,
but it still fails to account for a considerable propor-
tion of risk (c ¼ 0.578) (90).
These clinical risk scores divide the continuum
of stroke risk in patients with multiple risk factors
and are useful in stratifying the risks of stroke and
cardiovascular mortality in populations with and
without documented AF (91). Additional information
pertinent to thromboembolic risk may be obtained
from measurements of biomarkers, such as serum
troponin-I, CRP, and N-terminal pro–brain natriuretic
peptide (NT-proBNP); yet, even these supplemental
variables, either alone or in combination with the
CHA2DS2-VASc score, fail to fully account for the risk
of stroke attributable to nonvalvular AF (92).
The NT-proBNP fragment cleaved from the pro-
hormone to form the active natriuretic hormone
(brain natriuretic peptide [BNP]) is produced pri-
marily in the ventricles, but atrial production can
increase in patients with AF (93). Elevated levels of
NT-proBNP correlate with the burden of device-
detected AF independent of other factors known to
affect NT-proBNP (94), and predict recurrence after
catheter ablation of AF (95). BNP is synthesized and
secreted in bursts, in contrast to atrial natriuretic
peptide, which is stored in granules (96). Whether
BNP synthesis and secretion are impaired by the
myocyte necrosis that characterizes advanced atrial
ﬁbrosis is unknown. Although synthetic dysfunction
might be expected in this situation, BNP levels
remain elevated in patients with persistent AF (93).
When combined with clinical stroke risk factors,
ﬁbrosis as identiﬁed by DE-CMR correlates with LAA
thrombus on transesophageal echocardiography
(c ¼ 0.73) and clinical history of stroke (c ¼ 0.77)
(80,97). Serum levels of TGF-b1, antimuscarinic re-
ceptor 2 antibody, and procollagen I correlate with
ﬁbrosis severity detected by imaging, suggesting that
they have value as quantitative markers to improve
prediction of thromboembolic risk (98,99). However,
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and plasma BNP levels is a potentially important
missing pathophysiological link between atrial ﬁbro-
sis and thromboembolism.
BURDEN OF AF AND RISK OF STROKE
Compounding thrombogenicity engendered by atrial
ﬁbrotic cardiomyopathy and clinical stroke risk fac-
tors, the amount (frequency  duration) or burden of
AF can be assessed by a variety of electronic devices,
including dual-chamber pacemakers, deﬁbrillators,
resynchronization devices, and implanted loop re-
corders. The duration and frequency of device-
detected episodes of atrial tachyarrhythmias (ATs)
in patients with implanted pacemakers and de-
ﬁbrillators correlate with AF and stroke (100); thus,
these events cannot be dismissed as unimportant.
The burden of AF may affect the stroke risk for pa-
tients at high risk of stroke, so assessment of back-
ground risk is critical (101). Botto et al. (102) showed
that patients with a CHADS2 score of 0 had a very low
risk of thromboembolism (0.8%/year) regardless of
the burden of device-detected AT, whereas patients
with scores $3 had a high (5%/year) rate of ischemic
events. The duration of AT contributed most sub-
stantially to patients at intermediate risk (CHADS2
scores or 1 or 2). In patients with a CHADS2 score of 2,
just 5 min of device-detected AT increased the risk of
stroke, suggesting that electrically-signiﬁcant struc-
tural changes contribute to thromboembolic risk,
even during the early stages of the evolution of AF.
TEMPORAL DISSOCIATION OF ATRIAL
RHYTHM AND THROMBOEMBOLIC EVENTS
Whereas there is a clear correlation between the
duration and frequency (burden) of device-detected
episodes of AF and thromboembolism, a temporal
relationship between atrial high-rate episodes and
thromboembolic events has not been demonstrated.
On the contrary, several recent trials utilizing techno-
logical advances that provide continuous cardiac
monitoring have documented a clear dissociation
between the times subjects have AF and when their
strokes occur. In the TRENDS (Daily Atrial Tachyar-
rhythmia Burden from Implantable Device Diagno-
stics and Stroke Risk) study of 3,045 patients with
dual-chamber pacemakersmonitored for an average of
1.4 years, only 27.5% of the 40 patients developing
clinical thromboembolism exhibited ATwithin 30 days
before the event (103). Similarly, among 2,580 patients
followed a median of 2.5 years in ASSERT (Temporal
Relationship Between Subclinical Atrial Fibrillation
and Embolic Events Study), device-detected AT wasidentiﬁed in one-half of the 51 patients experiencing
ischemic stroke or systemic embolism, and only 8%
had AT within the prior 30 days (104).
Using a protocol intended to initiate and interrupt
oral anticoagulation guided by device-detected
AF, the IMPACT (Randomized Trial of Anticoagu-
lation Guided by Remote Rhythm Monitoring in
Patients with Implanted Cardioverter-Deﬁbrillator
and Resynchronization Devices) study conﬁrmed a
relationship between the burden of AF and stroke in
patients with implanted deﬁbrillators or resynchro-
nization devices (a population with more advanced
ventricular abnormalities than is typical of patients
with pacemakers and a considerably higher propor-
tion with clinical heart failure) (105). The device-
guided protocol failed to reduce the combined
primary endpoint of thromboembolism and major
bleeding, although compliance was suboptimal (106).
Adjudication of recorded atrial electrograms con-
ﬁrmed that the vast majority of device-detected AT
represented AF or atrial ﬂutter and that these ar-
rhythmias were temporally dissociated from stroke.
Taken together, studies in which atrial electrical
activity was continuously monitored challenge the
notion that AF, as an arrhythmia causing stagnation
of blood in the LA, is the proximate cause of strokes in
patients with implanted arrhythmia devices, even
though there was a clear relationship between the
burden of AF and stroke (Figures 3 and 4).
Among the plausible explanations are that stroke
in patients with AF involves mechanisms other than
cardiogenic embolism; that atrial structural abnor-
malities associated with AF may be thrombogenic,
even when the rhythm is normal or paced; or that
factors other than rhythm are responsible for the
migration of thrombus from the LA or LAA to the
systemic circulation. Regardless of which of these
alternatives alone or in combination is at play in a
given patient, electrocardiographic (or device-based)
documentation of AF should be regarded as a
marker of thromboembolic risk that warrants ongoing
prophylactic anticoagulation, tempered by the pa-
tient’s intrinsic risk of bleeding, but regardless of
whether or not the arrhythmia is sustained.
TRANSLATIONAL INTEGRATION OF
ATRIAL FIBROSIS IN CLINICAL MANAGEMENT
The interplay of atrial inﬂammation, ﬁbrillation,
ﬁbrosis, and thromboembolism has practical clinical
implications. Earlier identiﬁcation of individuals at
risk of developing the arrhythmia could better guide
both rhythm control and stroke prevention strategies.
Individual characteristics predispose to initiation and
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2246perpetuation of AF, as well as to stroke and systemic
embolism. A key question is whether AF is a root
cause of stroke or a marker that identiﬁes patients at
risk who would beneﬁt from chronic anticoagulation.
Early studies examining the association between AF
and stroke, such as the SPAF trials, found other riskal Dissociation Among Patients With an Embolic Event in the
d IMPACT Studies
f 
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lue; TRENDS in salmon; and IMPACT in gray. The percentage of AT/AF
time segments in relation to embolic event is shown. Abbreviations asfactors whose predictive value requires further veri-
ﬁcation. Complex plaque in the descending aorta was
a powerful echocardiographic predictor of ischemic
stroke, rather than a source of cerebral embolism,
pointing to the role of vascular disease and hyper-
tension in promoting the AF substrate (107).
In an observational study, Fuster et al. (108) found
lower rates of systemic embolism in patients with
dilated cardiomyopathy treated with systemic anti-
coagulation; the key contributing factor was AF. This
antedated trials that conﬁrmed the utility of anti-
coagulation for patients identiﬁed on the basis of AF
and the widespread availability of devices capable of
reliably detecting subclinical AF. A generation later,
percutaneous closure of the LAA was noninferior to
long-term warfarin therapy as a stroke prevention
strategy. Once again, stroke in patients with AF could
be ascribed to embolism of clots from the LAA
(109,110). Patients in the ﬁrst report of the PROTECT-
AF (Watchman Left Atrial Appendage System for
Embolic Protection in Patients with AF) study were
followed for an average of 18 months (108). Extended
follow-up of patients in this and the PREVAIL study
found lower mortality among recipients of the device,
largely as a consequence of avoiding major bleeding,
such as hemorrhagic stroke, compared with patients
continuing long-term warfarin therapy (109,110).
Evidence supporting cardiogenic embolism of LAA
thrombus as the most important mechanism of stroke
in patients with AF has mounted slowly, but con-
tinues to dominate the therapeutic rationale.
UNANSWERED QUESTIONS AND
FUTURE RESEARCH DIRECTIONS
DEFINING THE THERAPEUTIC PRIORITIES. If stasis
during AF or ﬂutter is the proximate cause of stroke,
maintenance of sinus rhythm should prevent embo-
lism. However, this has not been supported by the
results of randomized clinical trials, such as RACE and
AFFIRM (Atrial Fibrillation Follow-up Investigation of
Rhythm Management) (111,112). Available antiar-
rhythmic drugs have potential toxicity, invasive
catheter-based ablation strategies carry inherent risks,
and there is a paucity of evidence that successful ef-
forts to maintain sinus rhythm in patients with AF
ameliorate stroke risk enough to reduce the need for
chronic anticoagulant therapy. Management of pa-
tients with AF, therefore, focuses on control of the
ventricular rate, assessment of the risk of thrombo-
embolism, and judicious selection of candidates for
rhythm control. The principal criteria for a rhythm
control management strategy should be symptoms or
functional impairment directly attributable to the
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vagaries of symptom assessment (the most frequently
listed of which, fatigue, is also the most difﬁcult to
either quantify or assign a speciﬁc cause).
ADOPTING A HOLISTIC APPROACH TO STROKE
PREVENTION. More research is needed to ﬁndways to
reduce stroke risk by modifying the abnormal atrial
substrate that underlies most cases of AF. To date, this
has been limited, both conceptually and in terms of
clinical effect. Angiotensin receptor antagonists have
shown limited efﬁcacy in preventing AF, except in
speciﬁc settings in which the pathogenesis of the
arrhythmia and associated risk of thromboembolism
likely differ from those in more typical patients with
AF, such as the early period following cardiac surgery.
The signaling pathways involved in the development
of ﬁbrosis should be prime research targets, and
methods to redirect or transform the evolution of
atrial cardiomyopathy in relation to hypertension,
cardiomyocyte senescence, and other correlates of
aging must be at the fore to ensure ﬁndings relevant to
the largest possible segment of the population at risk.
TRANSLATING SUBSTRATE BIOLOGY INTO CLINICAL
ACTION. Inﬂammation and oxidative stress are
additional factors involved in the cascade of events
that culminates in permanent tissue injury, and these
represent potential pharmacologic marks. New
nonionic drugs that can inhibit atrial ﬁbrosis and cell
hypertrophy and modulate the inﬂammatory and
oxidative milieu have been proposed as upstream
therapeutic tools to attenuate atrial structural modi-
ﬁcations in patients with AF (27). These interventions
address ﬁbroblast proliferation and genetic links
to atrial ﬁbrosis. Furthermore, they complement
pulmonary vein isolation procedures that use less
thrombogenic energy sources to abolish atrial
arrhythmic foci and to ablate ﬁbrotic areas (substrate
modiﬁcation), and therefore, reduce post-procedural
inﬂammation and ﬁbrosis. A full evaluation of these
interventions ultimately takes us back to the need for
earlier identiﬁcation of atrial structural pathology.
The most far-reaching opportunities are directed at
preventing the ﬁbrotic atrial cardiomyopathy that con-
tributes to the inception, recurrence, and progression of
AF and its associated thromboembolic complications.
Among the potential targets is Cav-1, enhanced expres-
sion of which reverses the pathological atrial structural
remodeling in patients with AF. Interventions that
amplify the function of this or related scaffolding pro-
teins could potentially prevent or inhibit the develop-
ment of ﬁbrotic atrial cardiomyopathy.
Clinicians must synthesize decisions on the basis of
the interplay between atrial thrombogenicity andstasis related to AF. Atrial thrombogenicity varies in
rough proportion to the relatively ﬁxed (for variable
periods of time) severity of the anatomical and
structural aspects of ﬁbrotic atrial cardiomyopathy,
activation of platelets and the coagulation system
related to inﬂammatory and other potentially variable
factors, and the stasis associated with the arrhythmia
that occurs in the body of the LA and, to an even
greater extent, in the LAA, where blood is relatively
isolated from ﬂow patterns that develop passively
during ventricular diastole. Thrombus is most likely
to develop in proportion to the net duration of AF in
a given period—the burden of AF, but embolic
migration can occur either through random disrup-
tion of portions of the clot, endogenous lysis, or
variation in ﬂow dynamics that may arise with vari-
able latency in patients with paroxysmal AF after
restoration of sinus rhythm. This last consideration
also pertains to patients with infrequent episodes,
which are increasingly recognized as technological
innovations reveal device-detected AF in patients
with implanted pacemakers, deﬁbrillators, and
loop recorders. The future will doubtless see the
development of noninvasive methods—probably even
smartphone-based systems—capable of identifying
asymptomatic atrial high-rate episodes with implica-
tions for thromboembolism.
PERSONALIZING MANAGEMENT ON THE BASIS OF
CAUSALITY AND CONTEXT. Although the data
available to date have been derived mainly from
patients with more advanced forms of heart disease,
in whom detection of AF of almost any duration
might justify uninterrupted oral anticoagulation, we
must be prepared to adapt strategies to patients with
subclinical forms of atrial cardiomyopathy to initiate
the most appropriate type and intensity of anti-
thrombotic therapy before ischemic events occur.
Although studies of patients with therapeutic
implanted cardiac stimulators (pacemakers, de-
ﬁbrillators, or resynchronization devices) have gener-
ally found no temporal relationship between AF and
thromboembolism, chronologically closer and more
likely causal connections could exist in healthier pa-
tients with paroxysmal AF (113). Therapies that might
be ineffective for thosewith establishedAF and greater
thromboembolic risk may be better suited to those
with brief, infrequent episodes and less severe cardiac
pathology, for whom the net beneﬁt diminishes in
proportion to the risk of hemorrhage.
In the past, this duality was addressed by dis-
tinguishing higher-risk patients, who would beneﬁt
from anticoagulation with a vitamin K antagonist
(VKA) (e.g., warfarin), from those at lower risk, for
whom antiplatelet therapy with aspirin would sufﬁce.
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therapy became difﬁcult to verify in those with even a
single clinical stroke risk factor (114,115). The intro-
duction of the target-speciﬁc anticoagulant agents,
which have notable safety advantages over warfarin,
compounds the case against aspirin for most patients
with AF, except those at lowest risk, in whom the
beneﬁt of any antithrombotic therapy is difﬁcult to
verify. Because the tools conventionally utilized to
assess stroke risk are relatively primitive, biomarkers
and atrial tissue characteristics identiﬁed by high-
resolution imaging, such as ﬁbrosis and inﬂamma-
tion, may allow for more granular risk stratiﬁcation
and identify those who might beneﬁt from lower-
intensity antithrombotic therapy. Concurrently, we
must address the pre-ﬁbrillators—patients at risk of
developing AF, but inwhom the arrhythmia has not yet
developed or been documented—and merge these as a
continuum with others with low temporal burdens of
AF, in whom the risk of thromboembolism is expected
to mount over time, if for no other reason than aging.
MAKING THE LEAP FROM ARRHYTHMIA TO ATRIOPATHY.
We can today apply clinical risk stratiﬁcation schemes
to patients without overt AF and, by adding in fea-
tures predictive of progression of paroxysmal to
persistent AF, such as the HATCH (hypertension, age
older than 75 years, previous transient ischemic attack
or stroke, chronic obstructive pulmonary disease, and
heart failure) score (116), potentially identify patients
likely to develop AF and experience its thromboem-
bolic complications (117). Low-intensity antith-
rombotic therapy for such individuals need not be
conﬁned to aspirin alone. More intensive platelet in-
hibitor therapy, such as the combination of aspirin
plus clopidogrel, investigated in the ACTIVE-A (Atrial
Fibrillation Clopidogrel Trial with Irbesartan for Pre-
vention of Vascular Events—Aspirin) trial was more
effective than aspirin alone (118) among patients
deemed ineligible for anticoagulation (mean CHADS2
score w2). However, bleeding complications were
no less frequent than in those treated with a vitamin
K antagonist in ACTIVE-W (Atrial Fibrillation Clopi-
dogrel Trial with Irbesartan for Prevention of Vascular
Events: Clopidogrel plus aspirin versus Warfarin),
although most participants in the latter trial had suc-
cessfully tolerated anticoagulation before entry (119).
In the ENGAGE AF-TIMI 48 (Effective Anticoagulationwith Factor Xa Next Generation in Atrial Fibrillation—
Thrombolysis In Myocardial Infarction 48) trial (120)
of the oral factor Xa inhibitor edoxaban, a low-dose
regimen (30 mg daily, reduced to 15 mg if renal func-
tion deteriorated) barely satisﬁed the noninferiority
criterion for efﬁcacy against stroke and systemic em-
bolism compared to warfarin, yet it lowered all-cause
mortality, largely as a consequence of reduced
bleeding complications. A direct, prospective, mini-
mal intervention study comparing this or another low-
intensity antithrombotic regimen to aspirin, another
antiplatelet drug, or even no antithrombotic therapy
in patients with risk markers for thromboembolism
without AF or with low burdens of device-detected AF
would require a relatively large number of patients,
but the results could have broad implications for pri-
mary prevention of potentially devastating ischemic
events among the expanding elderly population.
Optimal strategies to prevent stroke related to AF
require earlier identiﬁcation of patients at risk of
developing the arrhythmia, development of upstream
strategies to prevent the atrial cardiomyopathy that
mediates the evolution and progression of AF, and
enhancing the accuracy and precision of thrombo-
embolism and bleeding risk assessment tools.
Furthermore, an objective understanding of individ-
ual patient characteristics should guide the clinician
choosing among an array of antithrombotic agents
and treatment strategies directed at rhythm control.
In addition to safer oral anticoagulant agents, abla-
tion catheters, and appendage occlusion methodol-
ogy, there are opportunities to target ﬁbrosis at the
molecular and genetic levels, alone and in combina-
tion. Links between aging, development of ﬁbrotic
atrial cardiomyopathy, and AF must be more clearly
delineated and then broken, allowing healthier aging
to proceed without the heart threatening the brain.
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